Peregrine Capital Management LLC Has $4.60 Million Stock Holdings in GeneDx Holdings Corp. $WGS

Peregrine Capital Management LLC increased its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 32.4% in the first quarter, Holdings Channel.com reports. The firm owned 71,572 shares of the company’s stock after purchasing an additional 17,534 shares during the quarter. Peregrine Capital Management LLC’s holdings in GeneDx were worth $4,596,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Kestra Advisory Services LLC bought a new position in GeneDx in the fourth quarter valued at approximately $27,000. Ramirez Asset Management Inc. bought a new stake in shares of GeneDx during the fourth quarter worth $33,000. Greenline Wealth Management LLC bought a new stake in shares of GeneDx during the fourth quarter worth $33,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of GeneDx during the fourth quarter worth $35,000. Finally, Quarry LP raised its holdings in shares of GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after acquiring an additional 209 shares during the period. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on WGS shares. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $75.00 target price (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Craig Hallum reissued a “buy” rating and issued a $85.00 price target on shares of GeneDx in a research note on Tuesday, May 5th. Zacks Research lowered GeneDx from a “hold” rating to a “strong sell” rating in a report on Monday. Wall Street Zen lowered GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings cut GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Six research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, GeneDx presently has an average rating of “Moderate Buy” and an average price target of $87.43.

GeneDx Price Performance

NASDAQ WGS opened at $71.71 on Thursday. The firm’s 50 day moving average is $54.43 and its 200-day moving average is $80.65. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $2.13 billion, a PE ratio of -26.76 and a beta of 1.89. GeneDx Holdings Corp. has a 12-month low of $32.21 and a 12-month high of $170.87.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The business had revenue of $102.25 million for the quarter, compared to analyst estimates of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same quarter in the previous year, the company posted ($0.23) EPS. Equities research analysts anticipate that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Insider Transactions at GeneDx

In related news, Director Keith A. Meister acquired 533,758 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was bought at an average price of $37.86 per share, for a total transaction of $20,208,077.88. Following the acquisition, the director directly owned 3,761,908 shares of the company’s stock, valued at approximately $142,425,836.88. The trade was a 16.53% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Casdin Capital, Llc bought 185,000 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average cost of $42.60 per share, for a total transaction of $7,881,000.00. Following the transaction, the director owned 3,367,164 shares of the company’s stock, valued at $143,441,186.40. The trade was a 5.81% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have bought 2,256,420 shares of company stock valued at $93,144,340 and have sold 21,699 shares valued at $1,295,646. Corporate insiders own 25.17% of the company’s stock.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Multiple law firms are reminding investors of the August 3, 2026 deadline to seek lead plaintiff status in the ongoing securities class action, which could support recovery efforts for affected shareholders. Article Title
• Neutral Sentiment: Several firms, including Rosen, Bernstein Liebhard, Faruqi & Faruqi, and others, are marketing representation for investors in the same class-action case, reinforcing that litigation risk remains a key overhang. Article Title
• Negative Sentiment: Zacks Research downgraded GeneDx from hold to strong sell, adding a fresh bearish signal for the stock. Article Title
• Negative Sentiment: The class action centers on alleged misstatements about the Fabric Genomics acquisition and cites a major stock collapse after weak Q1 2026 results and a $31.2 million impairment charge, highlighting operational and disclosure concerns. Article Title

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.